Symbiotec Pharmalab Limited IPO — the disclosed details
Closed
Symbiotec Pharmalab Limited is running a mainboard IPO on BSE and NSE, open for bidding from Monday, August 24 to Thursday, August 27, 2026, restated from the Red Herring Prospectus dated August 18, 2026 and the SEBI-hosted Abridged Prospectus. The price band and lot size are not confirmed in either primary document and are marked as reported.
This issue's bidding window has closed. What follows is the record of what was disclosed while the offer was open. It is not updated after the close, and it is not a view on the company or on how the shares have traded since.
Symbiotec Pharmalab Limited is running a mainboard IPO on BSE and NSE, open for bidding from Monday, August 24 to Thursday, August 27, 2026. This page restates what the company has disclosed in its Red Herring Prospectus dated August 18, 2026, and in the SEBI-hosted Abridged Prospectus, and nothing more. If the vocabulary is new — DRHP, price band, buckets, allotment — read how an Indian IPO actually works first.
What the company does
Symbiotec Pharmalab Limited manufactures Active Pharmaceutical Ingredients (APIs). APIs made up 96.07%, 99.10% and 100.00% of the company’s revenue from operations in Fiscals 2026, 2025 and 2024 respectively, per the RHP. Its manufacturing facilities are at Rau, Indore and at the Pithampur Special Economic Zone, both in Madhya Pradesh, and are subject to periodic inspections and audits by regulatory authorities — including the US FDA and the WHO’s and the EU’s Good Manufacturing Practice standards — and by customers. Revenue from the United States was 13.12%, 4.02% and 8.97% of revenue in Fiscals 2026, 2025 and 2024 respectively. The company’s registered office is at 385/2, Pigdamber, Rau, Mhow, Indore - 453 331, Madhya Pradesh.
What the money is for
The offer has two parts: the fresh issue — up to Rs 150.00 crore of new shares — is money that goes to the company; the offer for sale — up to Rs 1,607.00 crore of existing shares, sold by three selling shareholders — is money that goes to those shareholders, not the company.
The fresh-issue money has two stated objects:
| Object of the fresh issue | Amount, as filed |
|---|---|
| Prepayment and/or repayment, in full or in part, of certain outstanding borrowings | Rs 112.50 crore |
| General corporate purposes | Amount to be finalized upon determination of the Offer Price; shall not exceed 25% of the Gross Proceeds from the Fresh Issue |
| Selling shareholder | Offer for sale, up to |
|---|---|
| Satwani Holdings LLP (Promoter Selling Shareholder) | Rs 144.00 crore (WACA Rs 49.43/share) |
| Rosewood Investments (Investor Selling Shareholder) | Rs 988.00 crore (WACA Rs 147.21/share) |
| India Business Excellence Fund - III (Investor Selling Shareholder) | Rs 475.00 crore (WACA Rs 147.21/share) |
The weighted average cost of acquisition (WACA) figures above are certified by A B M S & Associates, Chartered Accountants, in a certificate dated August 18, 2026.
What the RHP flags as risks
This is the company’s own risk-factor section, paraphrased. It is disclosure, not commentary.
- Revenue concentration in APIs and top products. APIs made up 96.07%, 99.10% and 100.00% of revenue from operations in Fiscals 2026, 2025 and 2024 respectively; the top 5 products made up 62.27%, 63.16% and 60.37% of revenue over the same three fiscals, per the RHP’s narrative text and its own revenue data table. The SEBI-hosted Abridged Prospectus states the Fiscal 2026 figure as 67.27% instead — the RHP itself is internally consistent at 62.27% across both its narrative text and its underlying revenue table, and that is the figure used here.
- Regulatory inspections and FDA observations. The manufacturing facilities at Rau, Indore and the Pithampur Special Economic Zone, both in Madhya Pradesh, are subject to periodic inspections and audits by regulatory authorities, including the US FDA and the WHO’s and the EU’s Good Manufacturing Practice standards, and by customers. Both facilities have received US FDA Form 483 observations following their most recent inspections — Pithampur in 2023, Rau in 2026.
- US revenue exposure. Revenue from the United States was 13.12%, 4.02% and 8.97% of revenue in Fiscals 2026, 2025 and 2024 respectively.
- Customer concentration. The top ten customers accounted for 57.59%, 55.90% and 61.65% of revenue from sale of products in Fiscals 2026, 2025 and 2024 respectively.
- Single-region operations. Manufacturing facilities and dedicated R&D centres are concentrated in the state of Madhya Pradesh.
- Supplier concentration, including China. The company depends on certain suppliers, including from China, for raw materials. Purchases from its top ten suppliers were 25.50% and 18.41% of procurement in the two most recent disclosed fiscals (a further share is disclosed for the third). The RHP names China explicitly as an import-concentration and geopolitical-tension risk.
The numbers as filed
| Item | As filed |
|---|---|
| Issue size | Up to Rs 1,757.00 crore — fresh issue up to Rs 150.00 crore plus offer for sale up to Rs 1,607.00 crore |
| Fresh issue | Up to Rs 150.00 crore |
| Offer for sale | Up to Rs 1,607.00 crore, by three selling shareholders |
| Face value | Rs 2 per Equity Share |
| Price band | Rs 938 to Rs 988 per Equity Share, as reported |
| Lot size | 15 Equity Shares, and multiples of 15 thereafter, as reported |
| Minimum investment | Rs 14,820 for one lot (15 × Rs 988), at the as-reported cap price |
The RHP itself leaves the Floor Price, Cap Price and minimum Bid Lot as blank fields (“[]”), to be filled by a separate Price Band Advertisement; that advertisement was not found on any SEBI, exchange or company-hosted page as of 23 August 2026. The Rs 938–988 band and 15-share lot above are as reported by secondary IPO trackers and financial-media coverage, not confirmed against a primary filing. The minimum investment is arithmetic on those as-reported figures, not a line item printed in the RHP.
Financials, from the RHP’s Summary Financial Information, cross-checked against the SEBI-hosted Abridged Prospectus:
| Fiscal year | Revenue from operations | Total income | Profit after tax |
|---|---|---|---|
| Fiscal 2026 | Rs 869.15 crore | Rs 872.26 crore | Rs 109.90 crore |
| Fiscal 2025 | Rs 751.55 crore | Rs 755.98 crore | Rs 96.79 crore |
| Fiscal 2024 | Rs 716.25 crore | Rs 723.33 crore | Rs 100.06 crore |
Revenue from operations grew 15.65% in Fiscal 2026 and 4.93% in Fiscal 2025, per the RHP’s own KPI table.
Who can actually sell on listing day
On listing day, most of Symbiotec’s share register is not allowed to trade.
Here is what this RHP itself locks up, per its Capital Structure chapter. All periods run from the date of Allotment unless stated otherwise:
| Who | Locked for, per this RHP |
|---|---|
| Minimum Promoters’ Contribution — 20% of the fully diluted post-Offer Equity Share capital, under Regulations 14 and 16 of the SEBI ICDR Regulations | 18 months from the date of Allotment |
| Promoters’ shareholding in excess of that 20% | 6 months from the date of Allotment |
| All other pre-Offer Equity Shares, under Regulation 17, except shares sold in the Offer for Sale, shares held by employees under the ESOP Scheme, and shares held by a VCF, Category I AIF, Category II AIF or FVCI (locked instead for at least 6 months from the date of purchase by that shareholder) | 6 months from the date of Allotment |
| Anchor Investors — 50% of Anchor shares | 90 days from the date of Allotment |
| Anchor Investors — the other 50% | 30 days from the date of Allotment |
Only India Business Excellence Fund - III is registered as a Category II Alternative Investment Fund among current shareholders. The RHP does not state how many of its shares survive the Offer for Sale, so that exemption is noted here but not sized in the table below.
The count at the as-reported Rs 988 cap:
| Step | Shares | % of post-issue capital |
|---|---|---|
| Fresh issue | 1,518,218 | 2.36% |
| Offer for Sale | 16,265,182 | 25.31% |
| Total offer | 17,783,400 | 27.68% |
| Less: anchor allotment, locked 30/90 days | −5,325,909 | −8.29% |
| = Sellable on listing day | 12,457,491 | 19.39% |
| Locked or not offered — the rest of the register | 51,795,578 | 80.61% |
| Post-issue capital | 64,253,069 | 100.00% |
The anchor book is done — allotted at the as-reported Rs 988 price, around the Anchor Investor Bidding Date of Friday, August 21, 2026, aggregating approximately Rs 526.20 crore, per secondary IPO-tracker and financial-media reporting; no primary exchange-hosted anchor-allocation circular was found as of 23 August 2026. The fresh issue, offer-for-sale and anchor share counts in the table above are built on that same as-reported price band and are not confirmed against a primary filing; the RHP itself leaves all of these as blank (“[]”) fields pending the Price Band Advertisement.
A lock-in is not a forecast of anything — it is a restriction on selling; it says who may trade, not what the price will do.
These figures come from the RHP’s Capital Structure chapter, the SEBI-hosted Abridged Prospectus, and secondary price-band and anchor reporting where noted, as of 23 August 2026.
Dates and mechanics
| Event | Date |
|---|---|
| Anchor Investor Bidding Date | Friday, August 21, 2026 |
| Bid/Offer opens | Monday, August 24, 2026 |
| Bid/Offer closes | Thursday, August 27, 2026 |
| Finalisation of Basis of Allotment with the Designated Stock Exchange | On or about August 28, 2026 |
| Credit of shares to demat accounts | On or about August 31, 2026 |
| Commencement of trading of the Equity Shares on the Stock Exchanges | On or about September 1, 2026 |
The RHP marks every date after the close as indicative — “on or about” throughout.
The Offer is a Book Building Offer under Rule 19(2)(b) of the SCRR read with Regulation 31 of the SEBI ICDR Regulations, and in compliance with Regulation 6(1) of the SEBI ICDR Regulations. It is a mainboard offer proposed to list on NSE and BSE; BSE Limited is the Designated Stock Exchange. In-principle approvals were received from BSE and NSE vide letters each dated February 4, 2026.
| Bucket | Allocation |
|---|---|
| Qualified Institutional Buyers (QIB) | Not more than 50% of the Net Offer, of which the Company may allocate up to 60% to Anchor Investors (40% of the Anchor Investor Portion further reserved 33.33% for domestic Mutual Funds and 6.67% for Life Insurance Companies and Pension Funds); 5% of the resulting Net QIB Portion is reserved for Mutual Funds |
| Non-Institutional Investors (NII) | Not less than 15% of the Net Offer (one-third for applications above Rs 2 lakh up to Rs 10 lakh, two-thirds for applications above Rs 10 lakh) |
| Retail Individual Investors | Not less than 35% of the Net Offer |
| Employee Reservation Portion | Up to Rs 3.00 crore, not exceeding 5% of post-Offer paid-up Equity Share capital |
The book running lead managers are JM Financial Limited, Avendus Capital Private Limited, Motilal Oswal Investment Advisors Limited and Nomura Financial Advisory and Securities (India) Private Limited. The RHP discloses that Motilal Oswal Investment Advisors Limited is involved only in marketing the Offer, per its Regulation 21A(1)/23(3) SEBI Merchant Bankers Regulations conflict disclosure, though it has signed the due-diligence certificate and remains a disclosed BRLM. The registrar is MUFG Intime India Private Limited (formerly Link Intime India Private Limited).
Information as of 23 Aug 2026, taken from the offer documents and pages linked below. This is not an IPO review and no subscribe/avoid rating is given. Figures move through the issue lifecycle — check the filed documents before acting on any of them. Grey-market premium is an unofficial, unregulated price with no exchange record, and is not referenced here as information. Where the standing notice below refers to hypothetical figures, that covers the illustrative worked examples used in the options posts on this site — every number on this page is reproduced from the filed documents cited above.
This post is for educational purposes only and does not constitute investment advice or a recommendation to buy or sell any security or derivative contract. The author is not a SEBI-registered Research Analyst or Investment Adviser. Futures and options trading carries a high risk of loss and is not suitable for every investor — you can lose your entire premium, and more when selling naked. All figures and examples in this post, including the rupee premiums and price levels, are hypothetical and used only to illustrate the framework; they are not predictions, return promises, performance claims, or a recommendation to trade any specific instrument. Lot sizes and premiums change over time — always check current exchange data before trading. Please consult a SEBI-registered investment adviser before making any investment decisions.
Sources
- SEBI RHP filing index page — Symbiotec Pharmalab Limited →
- Red Herring Prospectus, dated August 18, 2026 (full 400+ page document, broker-hosted mirror; re-fetched and fully OCR'd to text this session via pdftotext for exhaustive verification, not just characterized) →
- SEBI-hosted Abridged Prospectus — Symbiotec Pharmalab Limited (re-fetched and OCR'd to text this session, used as a genuinely independent second primary source, not merely cited) →
- Business Standard — anchor round amount/date (secondary; re-attempted fetch this session, page returned HTTP 403 both sessions — headline/URL slug and search-snippet corroboration only) →
- TradingView (Reuters wire) — price band announcement (secondary; re-fetched this session, headline text "938-988 Rupees per Share" directly confirmed) →
- Chittorgarh IPO detail page (secondary tracker; direct fetch returned HTTP 403 again this session, used via search-result synthesis only) →
- BusinessToday — DRHP filing amount, December 2025 (secondary; re-confirmed this session) →
Common questions
How does IPO allotment work?
Applications are matched against the minimum lot size within each investor category (retail, HNI, QIB). In the retail category every applicant is first considered for one minimum lot: when the retail portion has enough shares to give every retail applicant one lot, everyone gets at least one and the surplus goes proportionately to those who bid more. Only when there aren't enough shares for one lot each is a computerised draw of lots used to pick who gets that single lot — and then each successful applicant gets exactly one lot, however many they bid for. It is never first-come-first-served, so applying early doesn't improve the odds.
What does the anchor investor lock-in mean?
Anchor investors (institutions allotted shares a day before the issue opens) are locked in and can't sell for a fixed period — and the clock runs from the date of Allotment, not from listing. Under the SEBI ICDR Regulations, 50% of the anchor shares are locked for 90 days from Allotment and the remaining 50% for 30 days from Allotment. It restricts anchors only; it says nothing about how retail-held shares will trade.
When do I get my money back if I'm not allotted?
Under ASBA, your bank only blocks the funds in your account — it's never debited until allotment. If you get no shares (or only a partial allotment), the block is released without any separate refund step: SEBI requires your bank (the SCSB) to complete the unblock by the close of banking hours on the working day after the basis of allotment is finalised — under the T+3 timeline, the day before the shares list. If it takes longer than that, SEBI's compensation policy provides ₹100 per day or 15% per annum of the application amount, whichever is higher — but it is complaint-triggered, so you have to raise it with your bank or the issue's lead manager to claim it.
What is ASBA / the UPI mandate?
ASBA (Application Supported by Blocked Amount) blocks the bid amount in your bank account instead of debiting it upfront. Retail investors bidding through UPI approve a mandate request in their UPI app, which blocks the funds — the money leaves your account only if shares are actually allotted.
The rest of the site
This page is a record of what was filed and published, and it stops there. The rest of the site is about the part that comes after you own something — how much of it to own, how to write the decision down, and how to grade it later.
Other issue pages from the same window
- Tempsens Instruments (India) Limited · 20 Aug 2026 – 24 Aug 2026
- Augmont Enterprises Limited · 21 Aug 2026 – 25 Aug 2026
- Hy-Tech Engineers Limited · 24 Aug 2026 – 27 Aug 2026
- Skyways Air Services Limited · 24 Aug 2026 – 27 Aug 2026
Everything on this site is free.
Every page here — the IPO desk, the chapter library, the trade journal tool — is free to read, with no paywall, nothing gated behind payment, and no affiliate links. If any of it has been useful, this is just a way to back the time that goes into writing it, checking the numbers, and keeping it honest.
No perks, no tiers, nothing unlocked for paying more. Just support for the work, if you want to give it. Pay what feels right.